SCHEMBL379535

SCHEMBL379535

C1CCC(P(C2CCCCC2)C2CCCCC2)CC1.C1CCC(P(C2CCCCC2)C2CCCCC2)CC1.C1CCC(P(C2CCCCC2)C2CCCCC2)CC1.C1CCC(P(C2CCCCC2)C2CCCCC2)CC1.[Pd]

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.32
HSD17B10 Q99714 1/20 0.32
MGLL Q99685 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6244133 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL3185955 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL1893030 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL27839473 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL139552 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL2168028 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL10548181 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL3180143 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
Hydrochloric Acid SCHEMBL6224383 0.96 ALDH1A1 (0.30) ALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL4506405 0.96 ALDH1A1 (0.30) ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507670-B2 Matrix metalloproteinase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-08-13 US claimed
CN-109563242-B Method for producing polymer compound 住友化学株式会社 2021-08-31 CN disclosed
EP-3197905-B1 METHOD FOR PRODUCING ETHYLENEDIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS, AND THE USE THEREOF AS FLAME RETARDANTS CLARIANT INT LTD (CH) 2021-06-30 EP disclosed
EP-3489274-A1 POLYMER COMPOUND PRODUCTION METHOD Sumitomo Chemical Company Limited (JP) 2019-05-29 EP disclosed
EP-3197905-A1 METHOD FOR PRODUCING ETHYLENEDIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS, AND THE USE THEREOF AS FLAME RETARDANTS Clariant Plastics & Coatings Ltd (CH) 2017-08-02 EP disclosed
EP-2379575-B1 HYDROPHOSPHORYLATION OF PHOSPHONIC ACID DERIVATIVES TO YIELD FLAME RETARDANTS CLARIANT INT LTD (CH) 2017-04-12 EP disclosed
WO-2016045976-A1 METHOD FOR PRODUCING ETHYLENEDIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS, AND THE USE THEREOF AS FLAME RETARDANTS CLARIANT INTERNATIONAL LTD (CH) 2016-03-31 WO disclosed
US-9279085-B2 Method for the production of monofunctionalized dialkylphosphinic acids, esters and salts, and use thereof CLARIANT FINANCE (BVI) LIMITED (VG) 2016-03-08 US disclosed
EP-2379572-B1 METHOD FOR THE PRODUCTION OF MONOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF CLARIANT INT LTD (CH) 2015-12-23 EP disclosed
US-9181487-B2 Process for preparing ethylenedialkylphosphinic acids, esters and salts by means of acetylene and use thereof CLARIANT FINANCE (BVI) LIMITED (VG) 2015-11-10 US disclosed
US-20100081610-A1 MATRIX METALLOPROTEINASE INHIBITORS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2010-04-01 US disclosed
EP-2074093-A2 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2009-07-01 EP disclosed
US-20090048413-A1 Method for Production of Conjugated Polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2009-02-19 US disclosed
WO-2009010188-A2 ALKYLPHOSPHONOUS ACIDS, SALTS AND ESTERS, METHODS FOR THE PRODUCTION THEREOF, AND USE OF SAME CLARIANT INTERNATIONAL LTD (CH) 2009-01-22 WO disclosed
EP-1997844-A1 METHOD FOR PRODUCTION OF CONJUGATED POLYMER Sumitomo Chemical Company, Limited (JP) 2008-12-03 EP disclosed
US-20080194565-A1 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2008-08-14 US disclosed
WO-2008023336-A2 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-02-28 WO disclosed
EP-1856063-A1 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES Ranbaxy Laboratories Limited (IN) 2007-11-21 EP disclosed
WO-2006090235-A1 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES RANBAXY LABORATORIES LIMITED (IN) 2006-08-31 WO disclosed
US-4230719-A Novel 2-[4-(3-methyl-2-thienyl)phenyl]propionic acid and pharmaceutically acceptable salt thereof and method for treating symptoms of inflammation and pain TOYAMA CHEMICAL CO., LTD. (JP) 1980-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081610-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP8, MMP12 ALDH1A1 1056/4885HSD17B10 448/4885MGLL 2490/4885
US-20080194565-A1 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases F2RL3, ACOX3, LPAR5 ALDH1A1 2132/4885HSD17B10 813/4885MGLL 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.